Lotte Biologics has secured its first large-scale commercial production order from a global pharmaceutical company ahead of the completion of Plant 1 at its Songdo Bio Campus in Incheon, South Korea. The company’s “pre-selling” strategy—courting customers from the plant design stage—has now produced tangible results.
Lotte Biologics said on the 17th that it signed a contract manufacturing (CMO) agreement for biopharmaceuticals with a global pharmaceutical company. It did not disclose specific terms, including the client’s name, contract value, or the products to be manufactured. The deal is significant as the first commercial production order for Songdo Plant 1, which is under construction with the aim of full operation in 2027.
The company plans to provide a one-stop service covering the entire process for the client’s flagship product, from clinical-stage drug substance to finished drug product. Because large-scale biopharmaceutical production facilities require massive upfront investment, profitability hinges on how quickly production volume can be secured after completion. Lotte Biologics said the contract allows it to establish a stable revenue base from the plant’s earliest days of operation.
Songdo Plant 1, where the ordered volume will be produced, is a biopharmaceutical production facility with a total capacity of 120,000 liters, featuring eight 15,000-liter stainless steel bioreactors. Construction is currently underway, with commercial production slated to begin in 2027.
CategoryDetailsContract typeBiopharmaceutical contract manufacturing (CMO)Production sitePlant 1, Songdo Bio Campus, IncheonProduction scale120,000 liters total (eight 15,000-liter bioreactors)Service scopeOne-stop, from clinical-stage drug substance to finished drug productCommercial production target2027
With this order, Lotte Biologics is expected to accelerate its “dual-site” strategy linking the Syracuse Bio Campus in the United States with the Songdo Bio Campus. The plan is to combine commercial production experience gained in Syracuse with Songdo’s large-scale production capacity to diversify the global supply chain and meet client demand.
The Syracuse Bio Campus has more than 62 regulatory approvals to its name and recently recorded “zero observations”—no findings—in a U.S. Food and Drug Administration (FDA) inspection. The company intends to apply Syracuse’s regulatory response experience and quality control know-how to the Songdo campus to build a consistent quality management system across its production sites in both countries.
James Park, CEO of Lotte Biologics, said, “This contract demonstrates that Lotte Biologics is establishing itself as a core supply chain partner for global clients, beyond being a mere new entrant to CDMO.” He added, “Based on our accumulated quality competitiveness and stable supply capabilities, we will actively support our clients’ successful commercialization of new drugs.”
In the global biopharmaceutical market, the importance of supply chain diversification and securing stable production bases is growing. As regulatory response experience and quality management capabilities—not just large-scale production capacity—are increasingly viewed as core competitiveness for CDMO companies, Lotte Biologics is highlighting that this contract marks the start of building actual commercial production orders, going beyond simply securing new production facilities.
However, with the contract size and client undisclosed, it remains difficult to gauge the impact of this order on plant utilization rates and financial results. Amid growing external uncertainties such as the global economic slowdown and the U.S. BIOSECURE Act, securing follow-up orders is seen as the key challenge. Lotte Biologics has set a goal of expanding its position in the global CDMO market based on its domestic and overseas production sites and rising to become a top-tier global CDMO company by 2030.